
Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY
On Oct. 15, 2021, Pfizer and BioNTech announced they had submitted data supporting the vaccination of children 5 to <12 years of age with COMIRNATY (COVID-19 mRNA vaccine) to the European Medicines Agency for a variation of the Conditional Marketing Authorization in the European Union (EU).
The variation request includes data from a Phase 2/3 study, which enrolled children 6 months to <12 years of age. The 2,268 participants who were 5 to <12 years of age received a 10-ᄉg dose level in a two-dose regimen administered 21 days apart. In the trial, the SARS-CoV-2ヨneutralizing antibody geometric mean titer was 1,197.6 (95% confidence interval [CI, 1106.1, 1296.6]), demonstrating strong immune response in this cohort of children one month after the second dose.
The same data have been submitted to the U.S. Food and Drug Administration and will be filed with other regulatory authorities in the coming weeks. Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.
COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are ongoing.
Tags:
Source: BioNTech
Credit:
